In a news release, surgical imaging company Imagin Medical Inc. (IME:CSE; IMEXF:OTCQB) announced that "its contract design and development firm Optel Inc. has delivered the functional i/Blue™ Imaging Systems that will be used to conduct in vivo studies and virtual demonstrations for evaluation by leading urologists."
Imagin Medical advised that its two i/Blue Imaging Systems functional units were initially selected for use in a first-in-human study assessing the final product design; however, medical institutions have recently suspended medical device clinical studies due to the COVID-19 situation. The company stated that it is currently pursuing other preclinical study options, but still plans to pursue first-in-human studies when clinical trials are permitted to resume.
The firm noted that it will utilize its other i/Blue functional units for use in virtual investor presentations and private meetings and demonstrations with medical professionals to generate additional interest and receive system performance feedback.
The company stated that it had originally planned to demonstrate i/Blue units and to meet with leading urologists this month at the annual American Urology Meeting in Washington, D.C. However, because the meeting was cancelled due to the COVID-19 pandemic, the company has implemented alternative plans that involve hosting virtual meetings to demonstrate the product's features and performance and to continue building contacts with key leading experts.
The company's President and CEO Jim Hutchens commented, "Receiving these i/Blue Systems is an exciting milestone and a major step forward. While in-person meetings and demonstrations of our i/Blue system would have been ideal, we are fortunate to have technologies to enable virtual meetings that will allow us to move forward."
Imagin Medical is a surgical imaging company based in Vancouver, B.C., that is engaged in developing new cancer visualization methods for use in minimally invasive surgical procedures, with its initial focus in the area of bladder cancer. The company stated that it believes "the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates."
Read what other experts are saying about:
Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Imagin Medical. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Imagin Medical. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Imagin Medical, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
